FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a crystalline compound effective for treating hyperproliferative diseases and having formula (I) 
,
wherein A+ represents a conjugated acid of tris(hydroxymethyl)aminomethane (Tris); X and Y independently represent chlorine having a fusion point of 103.37°C-105.77°C, and an X-ray powder diffraction spectrum is presented in Fig. 2, as well as to using it for treating various oncological diseases.
EFFECT: what is presented is a new crystalline compound possessing high stability, effective for treating hyperproliferative diseases.
15 cl, 32 dwg, 2 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS FOR CANCER TREATMENT INCLUDING ABX196 | 2017 |
|
RU2770432C2 |
| METHOD OF TREATING CANCER (VERSIONS) | 2006 |
|
RU2447889C2 |
| COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
| COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER, INCLUDING A VESSEL-DESTROYING AGENT AND A TAXANE COMPOUND | 2019 |
|
RU2761826C1 |
| SUPPRESSION OF CANCER METASTASES | 2010 |
|
RU2571502C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| NANOPARTICLES CARRYING CHEMOTHERAPEUTIC ANTI-CANCER THERAPEUTIC AGENT | 2012 |
|
RU2616494C2 |
| SYNERGISTIC COMBINATIONS OF AURISTANE | 2015 |
|
RU2717570C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING CANCER AND ITS METASTASES | 2006 |
|
RU2401662C2 |
